Vaccines Conference in Boston, September 23 - 25, 2009
The Vaccines Development Conference brings together scientists and industry experts in all aspects of vaccine development to share what’s working and not working for them, and to address your key vaccine development challenges and questions. The conference is held Boston, September 23 - 25, 2009.
Conference highlights:
Novel Adjuvant Development: Hear current advances in novel [...]
Cancer Vaccine: Vical Presents Positive Preclinical Results
Vical Incorporated presents encouraging results from animal studies of a peptide-based cancer vaccine formulated with the company’s Vaxfectin(R) adjuvant. Sean M. Sullivan, Ph.D., Vical’s Executive Director of Pharmaceutical Sciences, is presenting data at the IIRUSA Vaccines Development Forum (Boston - September 23-25) demonstrating the adjuvant’s ability to enhance immune responses of cancer antigen-based vaccines in [...]
HIV Vaccine: GenVec Receives Federal Funding
GenVec will receive up to $2.3 million for the 4th year to support the generation of HIV vaccine candidates with GenVec’s alternate adenovirus serotype technology. The National Institute of Allergy and Infectious Disease (NIAID) has executed its third option period (year four) under a previously announced, five-year contract with GenVec valued at up to $52 [...]
World Vaccine Congress Lyon 2009
World Vaccine Congress Lyon 2009, a Europe’s leading vaccine conference, will be held on October 5-8, 2009 in Lyon, France. The World Vaccine Congress Lyon is the annual vaccine conference addressing every aspect of vaccine research, vaccine development and vaccine manufacturing.
Highlights:
Representation from key European Commission and regulatory agencies
DG Research, DG SANCO, ECDC, EDQM, CHMP, VWP, [...]
Broad U.S. Patent Issued for Vaxfectin(R)-Formulated DNA Vaccines for Influenza
Vical Incorporated receives U.S. Patent No. 7,582,613 covering Vaxfectin(R)-formulated DNA vaccines for influenza. The patent provides broad coverage for any circulating or potential influenza viruses, including both seasonal and pandemic strains.
The company is currently developing Vaxfectin(R)-formulated DNA vaccines for both H5N1 avian-origin and H1N1 swine-origin pandemic influenza. Both vaccines are formulated with the company’s [...]
Chinese Vaccine Makers are Ready to Start Vaccine Production
The Chinese vaccine makers, Sinovac Biotech Ltd. and Hualan Biological Engineering Inc., have completed the clinical trials. Their products are claimed to be effective in single doses for population from three to 60 years. Sinovac claims the annual capacity to produce up to 30 million doses of swine flu vaccine, Hualan claims 160 million doses [...]
Synthetic Vaccine Platform Presented At Swine Flu Conference
The synthetic vaccine platform technology of Generex Biotechnology Corp. has been presented at the first International Swine Flu Conference in Washington, DC.
Douglas M. Powell, PhD, director of immunobiology at Antigen Express, a wholly owned subsidiary of Generex, described the advantages of suppressing a pandemic virus by next generation vaccines, such as Generex’s synthetic platform, [...]
Pandemic Vaccines: European Market Update
Global Pandemic Influenza Preparedness Market Forecast 2010-2015 - The report identifies issues and challenges for both the government as well as drug makers in addressing this market.
Four ‘mock-up’ vaccines developed by Baxter, GlaxoSmithKline and Novartis have already been approved in the European Union based on earlier data generated with the H5N1 virus strain, which is [...]
